How iMALDI can improve clinical diagnostics

dc.contributor.authorPopp, Robert
dc.contributor.authorBasik, M.
dc.contributor.authorSpatz, A.
dc.contributor.authorBatist, G.
dc.contributor.authorZahedi, R. P.
dc.contributor.authorBorchers, Christoph H.
dc.date.accessioned2020-10-20T16:45:09Z
dc.date.available2020-10-20T16:45:09Z
dc.date.copyright2018en_US
dc.date.issued2018
dc.description.abstractProtein mass spectrometry (MS) is an indispensable tool to detect molecular signatures that can be associated with cellular dysregulation and disease. Despite its huge success in the life sciences, where it has led to novel insights into disease mechanisms and the identification of potential protein biomarkers, protein MS is rarely used for clinical protein assays. While conventional matrix-assisted laser desorption/ionization (MALDI) MS is not compatible with complex samples, liquid chromatography-MS (LC-MS)-based assays may be too complex and may lack the robustness and ease of automation required for routine use in the clinic. Therefore, clinical protein assays are dominated by immunohistochemistry and immunoassays which, however, often lack standardization and fully depend on antibody specificity. Immuno-MALDI (iMALDI) MS may overcome these hurdles by utilizing anti-peptide antibodies for the specific enrichment of targeted analytes and on-target detection of the captured analytes, thus combining the unique properties of MS for the unambiguous detection and quantitation of analytes with a workflow that can be fully automated. Here we discuss the requirements for clinical protein assays, the pitfalls of existing methods, how iMALDI has been successfully used to quantify endogenous peptides and proteins from clinical samples, as well as its potential as a powerful tool for companion diagnostics in the light of precision medicine.en_US
dc.description.reviewstatusRevieweden_US
dc.description.scholarlevelFacultyen_US
dc.description.sponsorshipWe are grateful to Genome Canada and Genome British Columbia for financial support (project codes 264PRO, 204PRO for operations, and 214PRO for technology development). We would also like to thank Genome Canada, Genome British Columbia, and Genome Quebec for support for this project (project code 183AKT-GAPP). CHB is also grateful for support from the Leading Edge Endowment Fund (University of Victoria) and for support from the Segal McGill Chair in Molecular Oncology at McGill University (Montreal, Quebec, Canada). CHB, AS, MB, and GB are grateful for support from the Warren Y. Soper Charitable Trust and the Alvin Segal Family Foundation to the Jewish General Hospital (Montreal, Quebec, Canada). AS, MB, and GB are also grateful for support from Genome Canada’s Business-Led Networks of Centres of Excellence program, Exactis Innovations, and the Fonds de recherche du Québec – Santé, Axe cancer du sein et de l’ovaire (FRSQ-ACSO).en_US
dc.identifier.citationPopp, R., Basik, M., Spatz, A., Batist, G., Zahedi, R. P., & Borchers, C. H.(2018). How iMALDI can improve clinical diagnostics. Analyst, 143(10), 2197-2203. https://doi.org/10.1039/c8an00094hen_US
dc.identifier.urihttps://doi.org/10.1039/c8an00094h
dc.identifier.urihttp://hdl.handle.net/1828/12237
dc.language.isoenen_US
dc.publisherAnalysten_US
dc.titleHow iMALDI can improve clinical diagnosticsen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Popp_R_Analyst_2018.pdf
Size:
922.29 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: